--- title: "Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/295951890.md" description: "Ahmet Tezel, Chief Innovation Officer at LivaNova (NASDAQ:LIVN), sold 11,264 shares worth $876,682 on August 13, per SEC Form 4. The stock traded at $81.61, down 1.36%. LivaNova reported ~10.8% revenue growth, a 70.07% gross margin, and an EPS of 1.98. Valuation metrics suggest potential undervaluation with a P/E of 24.25 and P/S of 3.09, both below industry averages." datetime: "2026-08-14T15:04:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295951890.md) - [en](https://longbridge.com/en/news/295951890.md) - [zh-HK](https://longbridge.com/zh-HK/news/295951890.md) --- # Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock A substantial insider sell was reported on August 13, by **Ahmet Tezel**, Chief Innovation Officer at **LivaNova** (NASDAQ:LIVN), based on the recent SEC filing. **What Happened:** Tezel's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 11,264 shares of **LivaNova**. The total transaction value is $876,682. In the Friday's morning session, **LivaNova**'s shares are currently trading at $81.61, experiencing a down of 1.36%. ### Unveiling the Story Behind LivaNova UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. ### Breaking Down LivaNova's Financial Performance **Revenue Growth:** LivaNova displayed positive results in 3 months. As of 30 June, 2026, the company achieved a solid revenue growth rate of approximately **10.8%**. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers. **Insights into Profitability:** - Gross Margin: The company excels with a remarkable gross margin of 70.07%, indicating superior cost efficiency and profitability compared to its industry peers. - Earnings per Share (EPS): LivaNova's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.98. **Debt Management:** LivaNova's debt-to-equity ratio is below the industry average at **0.27**, reflecting a lower dependency on debt financing and a more conservative financial approach. **Understanding Financial Valuation:** - Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 24.25 is lower than the industry average, indicating potential undervaluation for the stock. - Price to Sales (P/S) Ratio: The current P/S ratio of 3.09 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): A high EV/EBITDA ratio of 21.21 positions the company as being more valued compared to industry benchmarks. **Market Capitalization Analysis:** The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers. ### The Relevance of Insider Transactions Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis. In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction. Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise. Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors. ### Cracking Transaction Codes Digging into the details of stock transactions, investors frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A **P** in Box 3 indicates a purchase, while **S** signifies a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of LivaNova's Insider Trades. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### Related Stocks - [LIVN.US](https://longbridge.com/en/quote/LIVN.US.md) ## Related News & Research - [LivaNova Chief Innovation Officer Ahmet Tezel disposes of shares worth $435,409.36](https://longbridge.com/en/news/295838616.md) - [LivaNova says Cardiopulmonary President Stefano Folli files initial beneficial ownership statement](https://longbridge.com/en/news/294946327.md) - [Andar Capital Management HK Ltd Takes $4.32 Million Position in FormFactor, Inc. $FORM](https://longbridge.com/en/news/296068767.md) - [Rocket Companies director Sarah Watterson files Form 3 initial beneficial ownership statement](https://longbridge.com/en/news/296141298.md) - [Insider Decision: Anthony Ibarguen Offloads $619K Worth Of Insight Enterprises Stock](https://longbridge.com/en/news/296247689.md)